Dr. Vladimir Vainstein

Vladimir is a Medical Doctor at the Hadassah Medical Center in Jerusalem. He holds a B.Sc. degree in Medical Sciences from the Hebrew University, M.D. degree from the Hebrew University / Hadassah Medical School, and an M.Sc. degree from the Department of Experimental Medicine and Cancer Research in the faculty of Medicine at the Hebrew University of Jerusalem. His M.Sc. research, carried out under the supervision of Prof. S.A. Ben-Sasson, involved the use of pathway inhibitors for the C-terminal post-translational modification of proteins as a possible avenue for developing anti-angiogenesis therapy. Dr Vainstein is a fellow in the Internal medicine Department at Hadassah Medical Center, Campus Mt. Scopus, Jerusalem. At IMBM he takes part in the immunotherapy project, developing methods for improving the efficacy of monoclonal antibody drugs by mathematically modeling the effects of such drugs on target and immune cells, and investigating data of survival of patients with myelodysplastic syndrome to better understand the pathophysiology of this disease by mathematical methods.

Scientific activity in 2009

  • Application of a human granulopoiesis model for optimization of chemotherapeutic and supportive treatment in cancer patients. Analysis of clinical data of drug-induced neutropenia for taxotere and temodal in collaboration with the Oncology Department of Soroka Hospital (Be'er-Sheva, Israel) and the Neuro-oncology Unit of Hadassah Medical Center (Jerusalem, Israel). The work was carried out with Oded Vainas and Zvia Agur as a joint project with Optimata, Ltd.
  • Implementation of a comprehensive model of the pharmacokinetics of cytotoxic monoclonal antibodies at the cellular level to experimental data of interaction of conjugated anti-CD33 antibodies with human leukemia cells (in collaboration with Drs. Eva Jager, Zvia Agur and V. van der Velden, Erasmus University, Rotterdam, Israel).
  • Development of the model of transformation of myelodysplastic syndrome into acute leukemia and using the database of MDS patients to evaluate model parameters. The model is designed to give insight into the biology of the disease’s transformation and help to develop ways to prevent or postpone it. This work is in collaboration with University of Dusseldorf (with Ofir Shukrun and Zvia Agur).

Conferences 2009

  • Population Approach Group Europe (PAGE) meeting 2009. June, St Petersburg, Russian Federation.

Work program for 2010

  • Further development of the MDS model to include individual patient-specific data. The research should improve the systems of evaluation of individual patient prognosis currently available.

Publications

  1. Arakelyan, L., Vainstein, V., & Agur, Z. (2002). A computer algorithm describing angiogenesis and vessel maturation and its use for studying the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth. Angiogenesis 5, 203–214.
  2. Vainstein, V., Ginosar, Y., Shoham, M., Yanovsky, A., Ranmar, D. & Agur, Z. (2005). The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. J Theor Biol. 234, 311–327.
  3. Arakelyan, L., Merbl, Y., Daugulis, P., Ginosar, Y., Vainstein, V., Kogan, Y., Sleitser, V., Harpak, H. & Agur, Z. (2003). Using multi-scale mathematical modeling in anti-angiogenic therapy. In Cancer modeling and simulation: Mathematical biology and medicine series. Chapman & Hall/CRC. 185-221.
  4. Vainstein, V., Ginosar, Y., Shoham, M., Ianovski, A., Rabinovich, A., Kogan, Y., Selitser, V., and Agur, Z. (2006). Improving Cancer Therapy by Doxorubicin and Granulocyte Colony-Stimulating Factor: Insights from a Computerized Model of Human Granulopoiesis. MMMP. 1(2), 70-80.
  5. Agur, Z., Elishmereni, M., Kogan, Y., Kheifetz, Y., Ziv, I., Shoham, M. & Vainstein, V. (2008). Mathematical modeling as a new approach for improving the efficacy/toxicity profile of drugs: the thrombocytopenia case study. In Preclinical development handbook. Ed. Gad, S.1229–1266. New York: John Wiley and Sons.
  6. Kronik, N., Kogan, Y., Vainstein, V. & Agur, Z, (2007). Improving alloreactive CTL immunotherapy for malignant gliomas by a computerized model. Cancer Immunol Immunother..57, 425–439.
  7. Kirnasovsky, O., Kogan, Y., Vainstein, V. & Agur Z, Investigation of tumour dynamics by mathematical modelling at the cellular level. In preparation.
  8. Jager, E., van der Velden, V.H.J, te Marvelde, J.G. & Vainstein, V. Physiologically-based mathematical model of targeted drug delivery: implications for choice of treatable patient population and treatment strategy. In preparation.

Abstractrs 2009

  • Arakelyan L, Vainstain V, and Agur Z. 2002. Optimizing anti-angiogenic therapy using mathematical tools. Proceedings of American Society of Clinical Oncology (ASCO), 21, p. 440a.
  • Harpak H, Cohen I, Ginosar Y, Ianovski A, Kogan Y, Shani M, Shoham M, Skomorovski K, Selitser V, Vainstein V & Agur Z, Using Virtual thrombopoiesis tool for identifying mechanisms of drug-induced thrombocytopenia and for defining patients of higher risk, Harpak H, Cohen I, Ginosar Y, Ianovski A, Kogan Y, Shani M, Shoham . Hematology Journal. 2003;4(suppl 2):224.
  • Harpak H, Cohen I, Ginosar Y, Ianovski A, Kogan Y, Shani M, Shoham M, Skomorovski K, Selitser V, Vainstein V & Agur Z. Using In Silico thrombopoiesis tool for identifying mechanisms of drug-induced thrombocytopenia and for defining patients of higher risk, EHO(2003).
  • Vainstein V., Ginosar Y., Shoham M., Ianovski A., Rabinovich A., Kogan Y., Selitser V., Ariad S., Chan S., Agur Z. Clinical validation of a physiologically-based computer model of human granulopoiesis and its use for improving cancer therapy by Doxorubicin and Granulocyte colony-stimulating factor (G-CSF). 48th Annual Meeting of the American Society of Hematology, Orlando, Florida, 9-12 December 2006.
  • Arakelyan L., Merbl Y., Vainstein V., Agur Z. A new cancer drug regimen based on the interplay between tumor growth and angiogenesis – Predictions of a mathematical model. SIAM Conference on the Life Sciences . Raleigh, North Carolina, 31July – 4 August 2006.

    • About IMBM | Scientific Board | IMBM Members | Research Projects | Applications
    Join Us | Press Release | Events | Publications | HOME